# Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT

> **NCT02027064** · PHASE4 · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Interferon-alpha

## Key facts

- **NCT ID:** NCT02027064
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-10
- **Primary completion:** 2017-10
- **Final completion:** 2017-10
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2016-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02027064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02027064, "Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02027064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*